Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03268551 · ClinicalTrials.gov registry record

MEMO-Medical Marijuana and Opioids Study

A clinical trial of Chronic Pain and Opioid Use, sponsored by Albert Einstein College of Medicine.

Completed
Registry status
257
Enrollment target
2
Study locations

NCT03268551: Completed study of Chronic Pain and Opioid Use, sponsored by Albert Einstein College of Medicine.

NCT03268551 is a study of Chronic Pain and Opioid Use that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 257 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03268551, a study of Chronic Pain and Opioid Use, has completed, sponsored by Albert Einstein College of Medicine.

COMPLETED
Registry status
257 participants
Enrollment target
2
Study locations

Study Summary

The study will examine how medical cannabis use affects opioid analgesic use over time, with particular attention to THC/CBD content, HIV outcomes, and severe adverse events.

Primary Outcome

The primary outcome will combine measures of prescribed and illicit opioid analgesic use.

Study Locations (2)

New York

  • Montefiore Health System - The Bronx
  • Vireo Health - White Plains

Trial Details

FieldValue
Enrollment Target 257 participants
Start Date 2018-09-04
Est. Completion 2023-07-14
Albert Einstein College of Medicine

175 total trials

What the finished NCT03268551 record still lists

NCT03268551 is an observational study that tracks outcomes without assigning an intervention. The registered 257 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (67% lower).

The record links to 4 conditions, with Chronic Pain appearing as the primary indexed condition, and to 0 interventions.

NCT03268551 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03268551 about?

NCT03268551 is a clinical study titled "MEMO-Medical Marijuana and Opioids Study". The study will examine how medical cannabis use affects opioid analgesic use over time, with particular attention to THC/CBD content, HIV outcomes, and severe adverse events.

What is the current status of trial NCT03268551?

This trial is currently completed. The enrollment target is 257 participants. The study started on 2018-09-04. Estimated completion is 2023-07-14.

What conditions does trial NCT03268551 study?

This clinical trial studies the following conditions: Chronic Pain, Opioid Use, HIV/AIDS, Marijuana.

Who is sponsoring clinical trial NCT03268551?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03268551 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03268551's enrollment target sits among peer trials

257 65th of 301 higher than 237 of 301 other Chronic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03618550 · 257 participants · Phase 2

    Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

  • NCT04674267 · 257 participants · NA

    Resilience and Equity in Aging, Cancer, and Health (REACH)

  • NCT06099288 · 257 participants · NA

    Strong Families Start at Home/Familias Fuertes Comienzan en Casa

  • NCT06207084 · 257 participants · NA

    The Fit With Us Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03268551, the US trial registry maintained by the National Library of Medicine. NCT03268551 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.